U.S. IVD And LDT For Autoimmune Diseases Market Size, Share & Trends Analysis Report By Typ, By Technology (Immunoassays, Clinical Chemistry, Hematology, Coagulation, Microbiology), By Application, By Country, And Segment Forecasts, 2024

Description

U.S. IVD And LDT For Autoimmune Diseases Market Growth & Trends:

The U.S. IVD and LDT for autoimmune diseases market size is expected to reach USD 3.70 billion by 2030, growing at a CAGR of 4.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The high prevalence of autoimmune disorders, growing awareness about these ailments, growing demand for technologically developed & high performance products, and high investments in research are the driving factors for the expanding growth of the market.

These health problems are second leading cause of chronic illness in the U.S. and are amongst the leading causes of deaths in the U.S. women. They have an adverse impact on the work productivity and the quality of life of patients and form an economic burden greatly affecting the healthcare spending in the U.S. The National Institute of Health estimates the direct healthcare costs associated with these disorders accounted for around USD 100 billion, whereas the cancer costs accounted for USD 57 billion.

A large number of people suffering from these disorders and rising prevalence at an alarming rate resulting in an increase of healthcare spending in the U.S. are all priority concerns, and is thus are expected to drive growth. Furthermore, the complications resulting from such health hazards like damage to internal organs, loss of mobility, and risk of death make it crucial for early diagnosis and intervention of such conditions. The rising awareness about these conditions is expected to lead market growth.

It is believed by number of researchers that the increase in the number of autoimmune diseases globally is due to the genetic predisposition and environmental factors. But there is very little knowledge about what exactly in the environment triggers the occurrence of autoimmune diseases. and mainly focused on commercial kits that are widely used by laboratories.

The FDA regulates IVD as medical devices however in the past it did not use its authority to regulate LDT. The FDA later announced that it would enforce its medical device regulatory authority to regulate the LDTs. Some researchers believe that the FDA regulation on LDTs would lead to an increase in the time and cost required to develop the tests.

U.S. IVD And LDT For Autoimmune Diseases Market Report Highlights:

In 2023, the IVD for rheumatoid arthritis was the leading segment with a revenue share of 12.14% and the LDT for rheumatoid arthritis had a share of 11.47%. The large number of diagnostic tests available for it as well as the high prevalence of the disease contributed to the market share.
In 2023, clinical chemistry was the leading segment with a market share of 32.37% in the IVD and 19.98% in the LDT. The diagnosis of autoantibodies in the blood is the most commonly employed diagnosis, thus contributing to the large share.
Crohn's disease is projected to grow at the fastest CAGR over the forecast period

Product Code: GVR-1-68038-287-7

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. U.S. IVD & LDT for Autoimmune Diseases Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Billion)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. U.S. IVD & LDT for Autoimmune Diseases Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. U.S. IVD & LDT for Autoimmune Diseases Market: Type Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. U.S. IVD & LDT for Autoimmune Diseases Market: Type Movement Analysis, 2023 & 2030 (USD Billion)
4.3. IVD
- 4.3.1. IVD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.4. LDT
- 4.4.1. LDT Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. U.S. IVD & LDT for Autoimmune Diseases Market: Technology Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. U.S. IVD & LDT for Autoimmune Diseases Market: Technology Movement Analysis, 2023 & 2030 (USD Billion)
5.3. Immunoassays
- 5.3.1. Immunoassays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.4. Clinical Chemistry
- 5.4.1. Clinical Chemistry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.5. Hematology
- 5.5.1. Hematology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6. Coagulation
- 5.6.1. Coagulation Machine Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.7. Microbiology
- 5.7.1. Microbiology Machine Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.8. Molecular Diagnostics
- 5.8.1. Molecular Diagnostics Machine Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.9. Other
- 5.9.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. U.S. IVD & LDT for Autoimmune Diseases Market: Application Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. U.S. IVD & LDT for Autoimmune Diseases Market: Application Movement Analysis, 2023 & 2030 (USD Billion)
6.3. Addison's Disease
- 6.3.1. Addison's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.4. Ankylosing Spondylitis
- 6.4.1. Ankylosing Spondylitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.5. Alopecia Areata
- 6.5.1. Alopecia Areata Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6. Rheumatoid Arthritis
- 6.6.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7. Systemic Lupus Erythematosus
- 6.7.1. Systemic Lupus Erythematosus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.8. Systemic Sclerosis
- 6.8.1. Systemic Sclerosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.9. Psoriasis
- 6.9.1. Psoriasis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.10. Antiphospholipid Antibody Syndrome
- 6.10.1. Antiphospholipid Antibody Syndrome Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.11. Diabetes Type 1
- 6.11.1. Diabetes Type 1 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.12. Crohn's Disease
- 6.12.1. Crohn's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.13. Ulcerative Colitis
- 6.13.1. Ulcerative Colitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.14. Narcolepsy
- 6.14.1. Narcolepsy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.15. Multiple Sclerosis
- 6.15.1. Multiple Sclerosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.16. Uveitis
- 6.16.1. Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Categorization
7.3. Company Heat Map Analysis
7.4. Company Profiles
- 7.4.1. Adaptive Biotechnologies Corporation
  - 7.4.1.1. Participant's Overview
  - 7.4.1.2. Financial Performance
  - 7.4.1.3. Product Benchmarking
  - 7.4.1.4. Recent Developments/ Strategic Initiatives
- 7.4.2. Agilent Technologies Inc.
  - 7.4.2.1. Participant's Overview
  - 7.4.2.2. Financial Performance
  - 7.4.2.3. Product Benchmarking
  - 7.4.2.4. Recent Developments/ Strategic Initiatives
- 7.4.3. Bio-Rad Laboratories, Inc.
  - 7.4.3.1. Participant's Overview
  - 7.4.3.2. Financial Performance
  - 7.4.3.3. Product Benchmarking
  - 7.4.3.4. Recent Developments/ Strategic Initiatives
- 7.4.4. bioMerieux, Inc.
  - 7.4.4.1. Participant's Overview
  - 7.4.4.2. Financial Performance
  - 7.4.4.3. Product Benchmarking
  - 7.4.4.4. Recent Developments/ Strategic Initiatives
- 7.4.5. Corgenix, Inc.
  - 7.4.5.1. Participant's Overview
  - 7.4.5.2. Financial Performance
  - 7.4.5.3. Product Benchmarking
  - 7.4.5.4. Recent Developments/ Strategic Initiatives
- 7.4.6. Johnson & Johnson Services, Inc.
  - 7.4.6.1. Participant's Overview
  - 7.4.6.2. Financial Performance
  - 7.4.6.3. Product Benchmarking
  - 7.4.6.4. Recent Developments/ Strategic Initiatives
- 7.4.7. Microbix Biosystems Inc.
  - 7.4.7.1. Participant's Overview
  - 7.4.7.2. Financial Performance
  - 7.4.7.3. Product Benchmarking
  - 7.4.7.4. Recent Developments/ Strategic Initiatives
- 7.4.8. PerkinElmer, Inc.
  - 7.4.8.1. Participant's Overview
  - 7.4.8.2. Financial Performance
  - 7.4.8.3. Product Benchmarking
  - 7.4.8.4. Recent Developments/ Strategic Initiatives
- 7.4.9. SQI Diagnostics Inc.
  - 7.4.9.1. Participant's Overview
  - 7.4.9.2. Financial Performance
  - 7.4.9.3. Product Benchmarking
  - 7.4.9.4. Recent Developments/ Strategic Initiatives
- 7.4.10. Thermo Fisher Scientific Inc.
  - 7.4.10.1. Participant's Overview
  - 7.4.10.2. Financial Performance
  - 7.4.10.3. Product Benchmarking
  - 7.4.10.4. Recent Developments/ Strategic Initiatives

U.S. IVD And LDT For Autoimmune Diseases Market Size, Share & Trends Analysis Report By Typ, By Technology (Immunoassays, Clinical Chemistry, Hematology, Coagulation, Microbiology), By Application, By Country, And Segment Forecasts, 2024 - 2030